Design and evaluation of levodopa methyl ester intranasal delivery systems.

  title={Design and evaluation of levodopa methyl ester intranasal delivery systems.},
  author={Inkoo Chun and Yeon Hong Lee and Kyung Eun Lee and Hye sun Gwak},
  journal={Journal of Parkinson's disease},
  volume={1 1},
OBJECTIVES This study aimed to examine the feasibility of nasal powder formulations for the delivery of levodopa (L-dopa) into the brain using highly water-soluble levodopa methyl ester hydrochloride (LDME). METHODS For designing nasal LDME powders, pH-rate stabilities of LDME in buffer solutions and their enzymatic degradations in rabbit nasal mucosal and serosal extracts were investigated. In vitro permeation studies were carried out with four LDME nasal powders. RESULTS LDME was degraded… 

Figures and Tables from this paper

Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems
  • Y. Lee, K. Kim, H. Gwak
  • Biology, Chemistry
    European Journal of Drug Metabolism and Pharmacokinetics
  • 2013
The results suggest that LDME nasal powder formulations would be useful delivery systems of l-dopa to the brain.
Formulation of levodopa containing dry powder for nasal delivery applying the quality‐by‐design approach
  • Csilla Bartos, E. Pallagi, I. Csóka
  • Materials Science
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2018
Development of a Hydrophobicity-Controlled Delivery System Containing Levodopa Methyl Ester Hydrochloride Loaded into a Mesoporous Silica
A 2-factor, 3-level full-factorial design was conducted to evaluate statistically the influence of the hydrophobicity of mesoporous silica on drug release of antiparkinsonian drugs, and indicated that the release rate significantly decreased with increasing hydrophOBicity.
In the present work attempts were made to deliver lamotrigine; a new antiepileptic drug, via intranasal route as mucoadhesive microspheres, developed by emulsion-solvent evaporation using chitosan as
Old Drugs, New Delivery Systems in Parkinson’s Disease
This review aims to provide up-to-date information about the newer delivery options for drugs used for Parkinson’s disease and provides a summary of infusion therapy with apomorphine, modifications to other dopamine agonists, various oral formulations of carbidopa/levodopa, inhaled levodOPA, intrajejunal infusion of levod opium, and sublingual apomorphicine.
Crystallization and physicochemical investigation of melevodopa hydrochloride, a commercially available antiparkinsonian active substance
In this work, the levodopa methyl ester was crystallized from different solvents and its physicochemical proper- ties were explored. This active pharmaceutical ingredient (API) is commercially
Novel levodopa formulations in the treatment of Parkinson's disease
IPX066 is a newly developed experimental formulation with a more favorable plasma profile than immediate-release levodopa, resulting in improved motor control and reduced dose frequency, which may increase adherence.
Perioperative sublingual levodopa in Parkisnon's Disease: A useful alternative!
Sublingual administration of tablet levodopamine as an alternative for perioperative administration of dopamine agonists worked well in patients and the same is described.


Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems.
Enhancement of the Systemic and CNS Specific Delivery of L-Dopa by the Nasal Administration of Its Water Soluble Prodrugs
Utilization of water soluble prodrugs of L-dopa via the nasal route in the treatment of Parkinson's disease may have therapeutic advantages such as improved bioavailability, decreased sideeffects, and potentially enhanced CNS delivery.
Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent.
Nasal absorption enhancement of insulin by sodium deoxycholate in combination with cyclodextrins.
Combining beta-CD with SDC lowered the serious nasal ciliotoxicity of SDC and had a marked absorption promoting effect, which was not due to low concentration of S DC but was related with the inhibition of LAP activity.
Mucosal drug delivery using cellulose derivatives as a functional polymer.
  • Y. Suzuki, Y. Makino
  • Biology
    Journal of controlled release : official journal of the Controlled Release Society
  • 1999
Impact of Gastric Emptying on Levodopa Pharmacokinetics in Parkinson Disease Patients
Fine tuning of LD application, which considers gastric emptying, becomes more and more essential in advanced PD stages with a reduced striatal neuronal dopamine capacity, which is responsible for maintenance of motor response in early PD patients.
Intranasal delivery: physicochemical and therapeutic aspects.
The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease.
Cyclodextrins in drug delivery: An updated review
Cyclodextrins, because of their continuing ability to find several novel applications in drug delivery, are expected to solve many problems associated with the delivery of different novel drugs through different delivery routes.
Levels of dopamine in blood and brain following nasal administration to rats.
  • M. Dahlin, B. Jansson, E. Björk
  • Biology, Medicine
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2001